Oral Corticosteroid Regimen for Moderate-to-Severe Asthma Exacerbation
For adults with moderate-to-severe asthma exacerbations, administer prednisone 40-80 mg daily (or prednisolone/methylprednisolone equivalent) in 1 or 2 divided doses for 5-10 days; for children, give 1-2 mg/kg/day (maximum 60 mg/day) for 3-10 days, with no taper needed for courses under 1 week. 1
Dosing Specifics
Adults
- Dose: 40-80 mg/day of prednisone (or equivalent)
- Frequency: Single daily dose or divided into 2 doses
- Duration: Continue until PEF reaches 70% of predicted or personal best, typically 5-10 days
- No taper required for courses ≤1 week; probably unnecessary even up to 10 days if patient is concurrently on inhaled corticosteroids 1
Children (≤12 years)
- Dose: 1-2 mg/kg/day (maximum 60 mg/day)
- Frequency: 2 divided doses
- Duration: 3-10 days until PEF reaches 70% of predicted or personal best
- No taper required for short courses 1
Route of Administration
Oral administration is preferred over intravenous - prednisone by mouth has equivalent efficacy to IV methylprednisolone but is less invasive and more practical 1. The evidence shows no advantage for IV administration unless gastrointestinal absorption is impaired 1, 2.
Alternative Corticosteroid Options
While prednisone/prednisolone remains the standard, dexamethasone is an acceptable alternative with potential advantages in adherence due to better palatability 3. However, a 2016 trial showed single-dose dexamethasone (12 mg) narrowly failed to meet noninferiority criteria compared to 5-day prednisone (60 mg/day), missing by a small margin (relapse rates: 12.1% vs 9.8%) 4. Despite this, enhanced compliance and convenience may support its use in selected patients.
Key Clinical Principles
Timing Matters
- Administer systemic corticosteroids early to all patients with moderate-to-severe exacerbations
- Give supplemental doses even for mild exacerbations in patients who regularly take corticosteroids 1
- Early administration may reduce hospitalization likelihood 1
Dose Considerations
- No proven advantage for higher doses in severe exacerbations 1
- The Cochrane review found no convincing evidence that higher doses or longer courses provide superior outcomes compared to lower doses or shorter courses 5
- Short courses (5 days) and lower doses provide comparable efficacy with improved tolerability 3
Duration Guidance
- Total course for ED visit or hospitalization: 3-10 days 1
- Continue until objective improvement (PEF ≥70% predicted/personal best)
- Courses <1 week require no taper 1
Common Pitfalls to Avoid
Don't delay administration - waiting for objective measurements wastes critical time; start corticosteroids promptly in moderate-to-severe presentations 1
Don't use unnecessarily high doses - no evidence supports doses above the recommended range, and higher doses increase adverse event risk without added benefit 1
Don't routinely taper short courses - tapering is unnecessary for courses ≤1 week and probably unnecessary up to 10 days if patient is on inhaled corticosteroids 1
Don't choose IV over oral reflexively - oral administration is equally effective and preferred unless absorption is compromised 1, 2
Don't forget concurrent inhaled corticosteroids - these can be started at any point during exacerbation treatment and facilitate discontinuation of systemic steroids 1
Safety Considerations
Multiple courses carry cumulative risk - while short courses are generally safe, receiving ≥4 courses may increase complication risk, particularly when combined with higher-dose inhaled corticosteroids 6. Balance the proven benefit in acute exacerbations against the need to optimize maintenance therapy to prevent future exacerbations requiring systemic steroids.